BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

598 related articles for article (PubMed ID: 27484989)

  • 1. Lack of concordance between residual viremia and viral variants driving de novo infection of CD4(+) T cells on ART.
    Puertas MC; Noguera-Julian M; Massanella M; Pou C; Buzon MJ; Clotet B; Stevenson M; Paredes R; Blanco J; Martinez-Picado J
    Retrovirology; 2016 Aug; 13(1):51. PubMed ID: 27484989
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dynamics of HIV tropism under suppressive antiretroviral therapy: implications for tropism testing in subjects with undetectable viraemia.
    Seclén E; Del Mar González M; De Mendoza C; Soriano V; Poveda E
    J Antimicrob Chemother; 2010 Jul; 65(7):1493-6. PubMed ID: 20488982
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Detection and quantification of proviral HIV-1 184 M/V in circulating CD4(+) T cells of patients on HAART with a viremia less than 1,000 copies/ml.
    Mohey R; Jørgensen LB; Møller BK; Black FT; Kjems J; Obel N
    J Clin Virol; 2005 Dec; 34(4):257-67. PubMed ID: 16286049
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CD4 T cell nadir independently predicts the magnitude of the HIV reservoir after prolonged suppressive antiretroviral therapy.
    Boulassel MR; Chomont N; Pai NP; Gilmore N; Sékaly RP; Routy JP
    J Clin Virol; 2012 Jan; 53(1):29-32. PubMed ID: 22019250
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Selective Decay of Intact HIV-1 Proviral DNA on Antiretroviral Therapy.
    Gandhi RT; Cyktor JC; Bosch RJ; Mar H; Laird GM; Martin A; Collier AC; Riddler SA; Macatangay BJ; Rinaldo CR; Eron JJ; Siliciano JD; McMahon DK; Mellors JW;
    J Infect Dis; 2021 Feb; 223(2):225-233. PubMed ID: 32823274
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Higher levels of HIV DNA in memory and naive CD4(+) T cell subsets of viremic compared to non-viremic patients after 18 and 24 months of HAART.
    Baldanti F; Paolucci S; Gulminetti R; Maserati R; Migliorino G; Pan A; Maggiolo F; Comolli G; Chiesa A; Gerna G
    Antiviral Res; 2001 Jun; 50(3):197-206. PubMed ID: 11397507
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Residual human immunodeficiency virus type 1 viremia in some patients on antiretroviral therapy is dominated by a small number of invariant clones rarely found in circulating CD4+ T cells.
    Bailey JR; Sedaghat AR; Kieffer T; Brennan T; Lee PK; Wind-Rotolo M; Haggerty CM; Kamireddi AR; Liu Y; Lee J; Persaud D; Gallant JE; Cofrancesco J; Quinn TC; Wilke CO; Ray SC; Siliciano JD; Nettles RE; Siliciano RF
    J Virol; 2006 Jul; 80(13):6441-57. PubMed ID: 16775332
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of raltegravir intensification on HIV proviral DNA in the blood and gut mucosa of men on long-term therapy: a randomized controlled trial.
    Chege D; Kovacs C; la Porte C; Ostrowski M; Raboud J; Su D; Kandel G; Brunetta J; Kim CJ; Sheth PM; Kaul R; Loutfy MR
    AIDS; 2012 Jan; 26(2):167-74. PubMed ID: 22089379
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pilot study of a combination of highly active antiretroviral therapy and cytokines to induce HIV-1 remission.
    Lafeuillade A; Poggi C; Chadapaud S; Hittinger G; Chouraqui M; Pisapia M; Delbeke E
    J Acquir Immune Defic Syndr; 2001 Jan; 26(1):44-55. PubMed ID: 11176268
    [TBL] [Abstract][Full Text] [Related]  

  • 10. HIV-1 X4/R5 co-receptor in viral reservoir during suppressive HAART.
    Soulié C; Marcelin AG; Ghosn J; Amellal B; Assoumou L; Lambert S; Duvivier C; Costagliola D; Katlama C; Calvez V
    AIDS; 2007 Oct; 21(16):2243-5. PubMed ID: 18090053
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Low-level plasma HIVs in patients on prolonged suppressive highly active antiretroviral therapy are produced mostly by cells other than CD4 T-cells.
    Sahu GK; Paar D; Frost SD; Smith MM; Weaver S; Cloyd MW
    J Med Virol; 2009 Jan; 81(1):9-15. PubMed ID: 19031450
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunologic and Virologic Parameters Associated With Human Immunodeficiency Virus (HIV) DNA Reservoir Size in People With HIV Receiving Antiretroviral Therapy.
    Blazkova J; Whitehead EJ; Schneck R; Shi V; Justement JS; Rai MA; Kennedy BD; Manning MR; Praiss L; Gittens K; Wender PA; Oguz C; Lack J; Moir S; Chun TW
    J Infect Dis; 2024 Jun; 229(6):1770-1780. PubMed ID: 38128541
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The effect of intensification with raltegravir on the HIV-1 reservoir of latently infected memory CD4 T cells in suppressed patients.
    Vallejo A; Gutierrez C; Hernandez-Novoa B; Diaz L; Madrid N; Abad-Fernandez M; Dronda F; Perez-Elias MJ; Zamora J; Muñoz E; Muñoz-Fernandez MA; Moreno S
    AIDS; 2012 Sep; 26(15):1885-94. PubMed ID: 22992577
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Persistence of wild-type virus and lack of temporal structure in the latent reservoir for human immunodeficiency virus type 1 in pediatric patients with extensive antiretroviral exposure.
    Ruff CT; Ray SC; Kwon P; Zinn R; Pendleton A; Hutton N; Ashworth R; Gange S; Quinn TC; Siliciano RF; Persaud D
    J Virol; 2002 Sep; 76(18):9481-92. PubMed ID: 12186930
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-term suppression of plasma viremia with highly active antiretroviral therapy despite virus evolution and very limited selection of drug-resistant genotypes.
    Pariente N; Pernas M; de la Rosa R; Gómez-Mariano G; Fernández G; Rubio A; López M; Benito JM; López-Galíndez C; Leal M; Domingo E; Martinez MA; Mas A
    J Med Virol; 2004 Jul; 73(3):350-61. PubMed ID: 15170628
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Factors associated with proviral DNA HIV-1 tropism in antiretroviral therapy-treated patients with fully suppressed plasma HIV viral load: implications for the clinical use of CCR5 antagonists.
    Soulié C; Fourati S; Lambert-Niclot S; Malet I; Wirden M; Tubiana R; Valantin MA; Katlama C; Calvez V; Marcelin AG
    J Antimicrob Chemother; 2010 Apr; 65(4):749-51. PubMed ID: 20150182
    [TBL] [Abstract][Full Text] [Related]  

  • 17. HIV-1 latent reservoir size and diversity are stable following brief treatment interruption.
    Salantes DB; Zheng Y; Mampe F; Srivastava T; Beg S; Lai J; Li JZ; Tressler RL; Koup RA; Hoxie J; Abdel-Mohsen M; Sherrill-Mix S; McCormick K; Overton ET; Bushman FD; Learn GH; Siliciano RF; Siliciano JM; Tebas P; Bar KJ
    J Clin Invest; 2018 Jul; 128(7):3102-3115. PubMed ID: 29911997
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Low-level viremia and proviral DNA impede immune reconstitution in HIV-1-infected patients receiving highly active antiretroviral therapy.
    Ostrowski SR; Katzenstein TL; Thim PT; Pedersen BK; Gerstoft J; Ullum H
    J Infect Dis; 2005 Feb; 191(3):348-57. PubMed ID: 15633093
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Changes in CD4+ and CD8+ T cell subsets in response to highly active antiretroviral therapy in HIV type 1-infected patients with prior protease inhibitor experience.
    Gray CM; Schapiro JM; Winters MA; Merigan TC
    AIDS Res Hum Retroviruses; 1998 May; 14(7):561-9. PubMed ID: 9591710
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Intensification of antiretroviral therapy with a CCR5 antagonist in patients with chronic HIV-1 infection: effect on T cells latently infected.
    Gutiérrez C; Díaz L; Vallejo A; Hernández-Novoa B; Abad M; Madrid N; Dahl V; Rubio R; Moreno AM; Dronda F; Casado JL; Navas E; Pérez-Elías MJ; Zamora J; Palmer S; Muñoz E; Muñoz-Fernández MÁ; Moreno S
    PLoS One; 2011; 6(12):e27864. PubMed ID: 22174752
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 30.